Brain-targeted, drug-loaded solid lipid nanoparticles against glioblastoma cells in culture

• DOI: 10.1016/j.colsurfb.2021.111946
• Publication Date: 2021-06-26T11:06:03Z
• Authors: Güliz Ak; Ayşe Ünal; Tuğba Karakayalı; Buket Özel; Nur Selvi Günel; Şenay Hamarat Şan...
• Keywords: Solid lipid nanoparticle; Carmustine; Temozolomide; Zeta potential; Biocompatibility

The aim of this study was the preparation of solid lipid nanoparticles (SLN) formed from cetyl palmitate with having targeting molecules for monocarboxylate transporter-1 (MCT-1): β-hydroxybutyric acid and anticancer agents: carmustine (BCNU) and temozolomide (TMZ) for enhanced anti-proliferation against glioblastoma multiforme (GBM). Properties including size, morphology, chemical structure, zeta potential, drug encapsulation efficacy, drug release, biocompatibility, stability were determined, and in vitro studies were done. BCNU and TMZ loaded SLNs had a hydrodynamic size of 227 nm ± 46 a zeta potential of -25 mV ± 4 with biocompatible features. The data showed rapid drug release at first and then continuous release. Nanoparticles could be stored for nine months. BCNU and TMZ loaded SLNs exhibited a remarkable increment in the antitumor activity compared to the free-drugs and induced apoptosis on U87MG cells. In addition, targeted nanoparticles were more uptaken by MCT-1 expressing brain cells. This study indicated that BCNU and TMZ loaded SLNs could act as a useful anticancer system for targeted GBM therapy.